Cargando…

The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation

The severe prognosis linked with a lung cancer diagnosis has changed with the discovery of oncogenic molecularly driven subgroups and the use of tailored treatment. ALK-translocated advanced lung cancer is the most interesting model, having achieved the longest overall survival. Here, we report the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bearz, Alessandra, De Carlo, Elisa, Del Conte, Alessandro, Spina, Michele, Da Ros, Valentina, Bertoli, Elisa, Revelant, Alberto, Stanzione, Brigida, Tirelli, Umberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266866/ https://www.ncbi.nlm.nih.gov/pubmed/35806325 http://dx.doi.org/10.3390/ijms23137322

Ejemplares similares

Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications
por: Del Conte, Alessandro, et al.
Publicado: (2022)

Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer
por: Stanzione, Brigida, et al.
Publicado: (2023)

Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era
por: De Carlo, Elisa, et al.
Publicado: (2022)

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
por: Bertoli, Elisa, et al.
Publicado: (2022)

Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
por: Bertoli, Elisa, et al.
Publicado: (2023)

NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease
por: Michelotti, Anna, et al.
Publicado: (2022)

Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report
por: Bearz, Alessandra, et al.
Publicado: (2014)

EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy
por: Reclusa, Pablo, et al.
Publicado: (2019)

Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC
por: Dai, Ying, et al.
Publicado: (2018)

A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC
por: Sampson, Josephina, et al.
Publicado: (2022)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience
por: De Carlo, Elisa, et al.
Publicado: (2018)

Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC
por: Weber, Daniel, et al.
Publicado: (2021)

Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system
por: Li, Siwen, et al.
Publicado: (2018)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

Identification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method
por: Maus, Martin K. H., et al.
Publicado: (2012)

Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system: Erratum
por: Li, Siwen, et al.
Publicado: (2020)

Identification of circulating tumor cells with EML4-ALK translocation using fluorescence in situ hybridization in advanced ALK-positive patients with lung cancer
por: Kim, Young Hun, et al.
Publicado: (2018)

Identification of circulating tumor cells with EML4-ALK translocation using fluorescence in situ hybridization in advanced ALK-positive patients with lung cancer
por: Kim, Young Hun, et al.
Publicado: (2019)

Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report
por: ALÌ, GRETA, et al.
Publicado: (2015)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC
por: Wang, Shasha, et al.
Publicado: (2022)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials
por: de Scordilli, Marco, et al.
Publicado: (2022)

Frequency and clinical relevance of EGFR mutations and EML4–ALK translocations in octogenarians with non-small cell lung cancer
por: Tufman, Amanda, et al.
Publicado: (2017)

Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report
por: De Carlo, Elisa, et al.
Publicado: (2018)

Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report
por: Liang, Wenhua, et al.
Publicado: (2016)

Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
por: Papageorgiou, Savvas, et al.
Publicado: (2022)

Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset
por: Guo, Yongjun, et al.
Publicado: (2014)

Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis: A Case Report
por: Wang, Wenxian, et al.
Publicado: (2016)

EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers
por: Fukuyoshi, Y, et al.
Publicado: (2008)

Thyroid metastasis from lung adenocarcinoma with EML4-ALK rearrangement
por: Kawamoto, Hironori, et al.
Publicado: (2016)

EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
por: Sabir, Sarah R., et al.
Publicado: (2017)

Endobronchial Metastases in Lung Cancer Harboring EML4-ALK Rearrangement
por: Ijichi, Miharu, et al.
Publicado: (2022)

Clinicopathological and Prognostic Significance of the EML4-ALK Translocation and IGFR1, TTF1, Napsin A Expression in Patients with Lung Adenocarcinoma
por: Bulutay, Pınar, et al.
Publicado: (2021)

CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma
por: An, Rong, et al.
Publicado: (2016)

The EML4-ALK oncogene: targeting an essential growth driver in human cancer
por: MANO, Hiroyuki
Publicado: (2015)

Targeting EML4-ALK gene fusion variant 3 in thyroid cancer
por: Aydemirli, Mehtap Derya, et al.
Publicado: (2021)

EML4-ALK fusion gene in non-small cell lung cancer
por: Lei, Yu, et al.
Publicado: (2022)

EML4-ALK Gene Mutation Detected with New NGS Lung Cancer Panel CDx Using Sputum Cytology in a Case of Advanced NSCLC
por: Morikawa, Kei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mvib1ks3s122ejfc5vqvnl4508